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The identification of specialized endothelial-cell populations in the blood vessels of bones, and their signalling 
pathways, reveals how the vasculature contributes to bone formation. See Article p.323 & Letter p.376 
 
The different structural and metabolic requirements of 
organs and tissues prompt the formation of specialized 
blood vessels during development1, which deliver 
molecules that instruct tissues on their fates2, 3. This 
process requires crosstalk between organs and the 
vasculature: organs generate local growth factors that 
attract blood vessels toward metabolically active regions, 
and the vessels release molecules (known as angiocrine 
signals) that affect cell differentiation in the developing 
organs. It is becoming increasingly clear that these 
interactions are influenced by the endothelial cells that 
line the inner surface of blood vessels. In two papers4, 5 in 
this issue, Adams and colleagues demonstrate that the 
bone vasculature contains specialized endothelial cells 
with signalling properties that support bone maturation 
and regeneration. As well as providing insight into the 
tissue specificity of angiocrine signalling, the findings 
have direct clinical relevance. 
In the first paper, Kusumbe et al.4 (page 323) began by 
mapping gene expression, metabolic activity and cell-
surface markers in the developing postnatal bone 
vasculature of mice. The authors distinguished two new 
subpopulations of endothelial cell (EC) that they term type 
H and type L ECs. Interestingly, they found that 
osteoprogenitor cells, which differentiate into bone-
forming osteoblasts, preferentially associate with type H 
ECs because these cells are a rich source of several 
growth factors relevant for the survival and proliferation of 
osteoprogenitors (Fig. 1). With age, however, both the 
type H EC and the osteoprogenitor populations decline. 
The authors also report that type H and type L ECs 
express different levels of the α-subunit of hypoxia-
inducible factor-1 (Hif-1α), a transcription factor that plays 
a central part in regulating cell metabolism and forming 
new blood vessels (angiogenesis)6. 
To assess the functional relevance of this protein in the 
endothelium, the authors genetically manipulated Hif-1α 
levels, and found that loss of the protein strongly reduced 
the number of type H ECs and osteoprogenitors, without 
affecting type L ECs. Conversely, enhanced Hif-1α 
expression increased the number of type H ECs, 
particularly in the metaphysis region of long bones, and 
this was accompanied by a significant increase in 
osteoprogenitor numbers and bone formation. 
The observation that proliferation of type H ECs and 
osteoprogenitor formation positively correlates with 
endothelial Hif-1α levels raised the idea that Hif-1α 
augmentation might induce angiogenesis and 
osteogenesis in aged animals, in which bone formation is 
impaired. To test this, the authors4 treated aged mice with 
deferoxamine mesylate (DFM), a chemical that inhibits 
Hif-1α degradation by targeting PHD enzymes, and 
observed a substantial expansion of type H ECs, 
osteoprogenitors and osteoblasts, and an increase in 
bone mass. These findings suggest that inducing type H 
ECs is key to maintaining bone remodelling during ageing. 
Ramasamy et al.5 (page 376) further investigated the 
crosstalk between the endothelium and osteogenesis by 
studying the endothelial Dll4–Notch signalling pathway, 
which has previously been defined as a negative regulator 
of angiogenesis in many organs7. Surprisingly, the authors 
found that Dll4–Notch signals positively regulate 
angiogenesis in postnatal long bones — highlighting the 
unusual properties of bone endothelium. Loss of 
endothelial Notch signalling in mice was associated with 
reduced bone mass and shortening of long bones and, 
conversely, activating these signals augmented 
osteogenesis and bone size. In line with type H ECs 
playing a key part in bone blood-vessel growth and 
osteogenesis, this cell population increased on activation 
of endothelial Notch. 
The authors5 next analysed factors secreted by ECs in 
mice that were genetically engineered to have active 
Notch signalling, and found a strong upregulation of 
Noggin, an antagonist of growth factors collectively known 
as bone-morphogenetic proteins. Administering Noggin to 
Notch-deficient mice restored angiogenesis and bone 
formation, and the molecular mechanism underlying this 
rescue was traced to effects of Noggin on restoring both 
local expression of the protein Sox9, which is relevant for 
initiating the cartilage–bone transition, and levels of 
vascular endothelial growth factor. Thus, Notch and the 
angiocrine release of Noggin link the type H endothelium 
to osteogenesis. 
These findings generate several questions. For example, 
how can Notch signalling switch between negative7 and 
positive regulation of angiogenesis in a tissue-specific 
manner? Ramasamy and co-workers suggest that this 
may involve Hes5, a transcription-regulating protein that 
acts downstream of Notch, but other environmental and 
tissue-specific cues may be involved. The demonstration 
that Hif-1α is crucial in maintaining the type H EC 
population, but that these cells are lost in aged animals, 
suggests that loss of Hif-1α signalling may be involved in 
age-related bone changes. If so, what regulates Hif-1α in 
aged animals? Obvious candidates for involvement in Hif-
1α degradation are the oxygen-sensitive PHD enzymes8. 
Also, do the Notch and Hif-1α signalling cascades 
interdependently regulate the type H endothelium? And 
might changes in EC populations affect other bone cells, 
such as haematopoietic stem cells in the endosteum 
tissue layer of bones? 
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In addition to prompting these biological questions, 
Adams and colleagues' work4, 5 has important clinical 
implications. Bone is continually deposited by osteoblasts, 
which are activated by bone fractures. But osteoblast 
activity declines with age, leading to bone loss and 
impaired fracture healing. This age-related osteoporosis is 
the most common cause of all bone diseases, and is 
associated with other health problems and deaths, 
especially in post-menopausal women. Osteoporosis is 
also a frequent complication in patients receiving long-
term corticosteroid treatment following organ 
transplantation. The data provided by these and other9 
mouse studies suggest that DFM treatment might help to 
restore bone-formation deficits. DFM is registered for 
clinical use, currently for the treatment of iron-overloaded 
patients and in combination with dialysis, so clinical trials 
to examine the drug in the context of osteoporosis are 
foreseeable. DFM might also be considered as a 
combined therapy with bisphosphonate drugs10, which are 
used to slow the loss of bone. 
Excessive bone loss can also result from the reduced 
gravitational forces experienced during long periods of 
space travel. Coincidentally, the character Nog from Star 
Trek: Deep Space Nine shares the same name as the 
abbreviation for the protein Noggin, implicated by Adams 
and colleagues in bone formation. Only time will tell if this 
coincidence demonstrates foresight. 
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Figure 1: Type H endothelial cells couple angiogenesis to osteogenesis. 
Kusumbe et al.4 and Ramasamy et al.5 define type H endothelial cells (ECs) as a specialized population in the bone 
vasculature that induces the formation of new blood vessels (angiogenesis) in bone. Type H ECs secrete the protein 
Noggin, which sustains the osteoblast and chondrocyte cells that are responsible for bone formation. In return, these 
cells secrete vascular endothelial growth factor (VEGF), which supports angiogenesis. The authors also show that 
the proliferation of type H ECs is positively regulated by the Hif-1α and Dll4–Notch signalling pathways. Accordingly, 
they find that administration of the drug DFM, which inhibits PHD enzymes that degrade Hif-1α, leads to increased 
numbers of type H ECs, enhanced differentiation of osteoblast-progenitor cells and increased bone formation in aged 
mice. 
